Reduction of the potential anticancer drug oracin in the rat liver in-vitro

Journal of Pharmacy and Pharmacology

Volumn 52, Issue 5, 2000, Pages 495-500

  Szotáková, Barbora ^a   Skálová, Lenka ^a   Wsól, Vladimír ^a   Kvasnièčková, Eva ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 18ALPHA GLYCYRRHETINIC ACID; 3 METHYLCHOLANTHRENE; ALPHA NAPHTHOFLAVONE; ANTINEOPLASTIC AGENT; CARBONYL REDUCTASE; CYTOCHROME P450; METYRAPONE; ORACIN; QUERCITRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INDUCTION; IN VITRO STUDY; INHIBITION KINETICS; LIVER; LIVER CYTOSOL; LIVER MICROSOME; MALE; NONHUMAN; RAT; REDUCTION;

EID: 0343618430     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357001774273     Document Type: Article

References (31)

1. Akao, T., Terasawa, T., Hiai, S., Kobashi, K. (1992) Inhibitory effects of glycyrrhetic acid derivatives on 11β- and 3α-hydroxysteroid dehydrogenases of rat liver. Chem. Pharm. Bull. 40 (11): 3021-3024
2. Büld, J., Mangoura, S. A., Maser, E. (1996) Developmental changes in carbonyl reductase activity in mouse liver and kidney cytosol. Exp. Toxic. Pathol. 48: 51-57
3. Felsted, R. L., Bachur, N. R. (1980) Ketone reductases. In: Jakoby, W. B. (ed) Enzymatic Basis of Detoxication. Academic Press Inc., London, pp 281-293
4. Geršl, V., Mazurová, Y., Bajgar, J., Mělka, M., Hrdina, R., Palička, V. (1996) Lack of cardiotoxicity of a new anti-neoplastic agent, a synthetic derivative of indenoisochinoline: comparison with daunorubicin in rabbits. Arch. Toxicol. 70: 645-651
5. Gillette, J. R. (1972) Techniques for studying drug metabolism in vitro. In: La Du, B. N., Mandel, H. G., Way, E. L. (eds) Fundamentals of Drug Metabolism and Drug Disposition. The Williams and Wilkins Company, Baltimore, pp 400-418
6. Goeptar, R. A., Scheerens, H., Vermeulen, N. P. E. (1995) Oxygen and xenobiotic reductase activities of cytochrome P450. Crit. Rev. Toxicol. 25: 25-65
7. Lubet, R. A., Mayer, R. T., Cameron, J. W., Nims, R. W., Burke, M. D., Wolf, T., Guengerich, F. P. (1985) Dealkylation of penthoxyresorufin: a rapid and sensitive assay for measuring induction of cytochromes P450 by phenobarbital and other xenobiotics in the rat. Arch. Biochem. Biophys. 83: 43-48
8. Marhan, J. (1995) Mutagenicity of cytostatic drugs in a bacterial system. I. Ames test. Folia Microbiol. 40: 457-461
9. Markwell, M. A. K., Haas, S. M., Bieber, L. L., Tolbert, N. E. (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87: 206-210
10. Maser, E. (1996) 11β-Hydroxysteroid dehydrogenase acts as carbonyl reductase in microsomal phase I drug metabolism. Exp. Toxic. Pathol. 48: 266-273
11. Maser, E. Bannenberg, G. (1994) The purification of 11β-hydroxysteroid dehydrogenase from mouse liver microsomes. J. Steroid Biochem. Mol. Biol. 48: 257-263
12. Maser, E., Richter, E., Friebertshäuser, J. (1996) The identification of 11β-hydroxysteroid dehydrogenase as carbonyl reductase of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Eur. J. Biochem. 238: 484-489
13. Mazel, P. (1972) Experiments illustrating drug metabolism in vitro. In: La Du, B. N., Mandel, H. G., Way, E. L. (eds) Fundamentals of Drug Metabolism and Drug Disposition. The Williams and Wilkins Company, Baltimore, pp 546-582
14. Mělka, M. (1993) Preclinical Summary report RIPB
15. Michalský, J. (1992) International Patent Application, PCT/CS92/00026
16. Monder, C., Shackleton, C. H. (1984) 11 Beta-hydroxysteroid dehydrogenase: fact or fancy? Steroids 44: 383-417
17. Omura, T., Sato, R. (1964) The carbon-monoxide-binding pigment of liver microsomes. II. Solubilization, purification, properties. J. Biol. Chem. 239: 2379-2385
18. Oppermann, U. C. T., Maser, E., Mangoura, S. A., Netter, K. J. (1991) Heterogeneity of carbonyl reduction in subcellular fractions and different organs in rodents. Biochem. Pharmacol. 42: S189-S195
19. Oppermann, U. C. T., Persson, B., Jörnvall, H. (1997) The 11β-hydroxysteroid dehydrogenase system, a determinant of glucocorticoid and mineralocorticoid action. Function, gene organization and protein structures of 11β-hydroxysteroid dehydrogenase isoforms. Eur. J. Biochem. 249: 355-360
20. Ortiz de Montellano, P. R. Reich, N. O. (1986) Inhibition of cytochrome P-450 enzymes. In: Ortiz de Montellano, P. R. (ed) Cytochrome P-450. Structure, Mechanism and Biochemistry. 1st Edn, Plenum Press, New York, pp 273-314
21. Pröpper, D., Maser, E. (1997) Carbonyl reduction of daunorubicin in rabbit liver and heart. Pharmacol. Toxicol. 80: 240-245
22. Souček, P. Gut, I. (1992) Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 22: 83-103
23. Skálová, L., Wsól, V., Szotáková, B., Kvasničková, E. (1999) A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomers in vitro in rat and guinea pig. Chirality 11: 510-515
24. Szotáková, B., Wsól, V., Trejtnar, F., Skálová, L., Kvasničková, E. (1996) Studies on the metabolism of the potential cytostatic drug oracin. Species differences. Exp. Toxic. Pathol. 48 (Suppl. II): 377-380
25. Szotáková, B., Wsól, V., Kvasničková, E. (1998) Methods for the detection and characterization of metabolites of the potential cytostatic drug oracin. Folia Pharm. Univ. Carol. 21-22: 43-51
26. Szotáková, B., Wsól, V., Skálová, L., Kvasničková, E. (1999) Role of cytochrome P4501 A in biotransformation of the potential anticancer drug oracin. Exp. Toxic. Pathol. 51: 164-167
27. Wermuth, B. (1985) Aldo-keto reductases. Prog. Clin. Biol. Res. 174: 209-230
28. Wermuth, B., Bohren, K. M., Heinemann, G., Von Wartburg, J., P., Gabbay, K. H. (1988) Human carbonyl reductase. Nucleotide sequence analysis of a cDNA and amino acid sequence of the encoded protein. J. Biol. Chem. 263: 16185-16188
29. Wsól, V., Kvasničková, E., Szotáková, B., Hais, I. M. (1996) High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracin. J. Chromatogr. B 681: 169-175
30. Wsól, V., Szotáková, B., Kvasničková, E., Fell, A. F. (1998) High-performance liquid chromatography study of stereo-specific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison. J. Chromatogr. A 797: 197-201
31. Wsól, V., Skálová, L., Szotáková, B., Kvasničková, E. (1999) Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo. Chirality 11: 505-509